The FMHR traders debate the play on large cap versus small cap biotech stocks.» Read More
The FMHR traders discuss what warning signs bull investors should be looking for in the stock market and concerns about a biotech bubble.
U.S. lawmakers sent a letter to Gilead requesting information on pricing for its hepatitis c drug Sovaldi. Christopher Raymond of R.W. Baird.
Discussing the market's big reaction to news U.S. lawmakers requested information about Gilead's hepatitis C drug Sovaldi, and which stocks are attractive in the sector, with Geoff Porges, Bernstein Research senior analyst.
CNBC's Dominic Chu reports the health care sector is being dragged down by the biotech sector. Congressional Democrats asked biotech company Gilead to provide insight on pricing for its hepatitis C drug Sovaldi.
CNBC's Sheila Dharmarajan reports on the decline in the Nasdaq because of the hit to the biotechs. Gilead received a letter from senior Democrats requesting a briefing on the pricing for its hepatitis C drug Sovaldi.
MediWound develops treatments for severe burns and hard to heal wounds. Gal Cohen, MediWound CEO, discusses his company's medical solutions and the results of its IPO.
CNBC's Bob Pisani discusses the IPO of Castlight Health and how classic momentum stocks are trading, and CNBC's Sheila Dharmajan looks at what biotech stocks are getting hit hard.
CNBC's Bertha Coombs discusses potential froth in the biotech sector due to an uptick in biotechnology IPOs.
FMHR traders Mike Murphy and Pete Najarian debate the play on the S&P biotech ETF.
Biotech firm Dendreon is set to begin selling its prostate cancer vaccine "Provenge" in Europe. John Johnson, Dendreon chairman & CEO, discusses the European launch and addresses investor concerns.
Sam Isaly of OrbiMed Advisors, explains why he likes the new products of Regeneron, and why he expects Intermune to go higher.
CNBC's Bertha Coombs reports on which sectors and stocks are impacted by Obamacare, and the FMHR traders share their top health care stock picks.
Barbara Ryan, FTI Consulting managing director, analyzes the biotech sector and reveals which companies are on the forefront of therapies worth investing in.
Steven St. Peter, Aratana Therapeutics president & CEO, discusses the need for pet medical pharmaceuticals and the market for pet insurance.
CNBC's Sheila Dharmarajan reports on what factors contribute to the biotech sector outperforming this year.
LONDON, Jan 29- In experiments that could open a new era in stem cell biology, scientists have found a simple way to reprogramme mature animal cells back into an embryonic-like state that allows them to generate many types of tissue.
LONDON, Jan 29- In experiments that could open a new era in stem cell biology, scientists have found a cheap and easy way to reprogramme mature cells from mice back into an embryonic-like state that allowed them to generate many types of tissue.
As Bristol-Myers Squibb prepares to report its Q4 earnings on Friday, CNBC's Morgan Brennan and Seamus Fernandez, Leerink Partners managing director & pharma analyst, discuss if now is the time to invest in the biotech.
Mark Schoenebaum, ISI Group analyst, breaks down the red hot biotech sector and explains why Gilead Sciences is his best play.
Dan Fitzpatrick, StockmarketMentor.com president & technical analyst, takes a look at the charts to get a technical read on Twitter. Also a look at why Fitzpatrick likes the biotech sector.